Nimesulide derivatives reduced cell proliferation against breast and ovarian cancer: synthesis, characterization, biological assessment, and crystal structure.

New nimesulide derivatives (A1-A6) were synthesized and investigated by IR, 1H NMR, 13C NMR, melting point, elemental analysis, mass spectra, and DSC analysis. Agent A3 single crystal was grown and solved in a monoclinic crystal system with Cc. Heat shock protein 27 (HSP27) and tubulin are essential cellular proteins for normal cell division and growth. In addition, these proteins are expressed highly in cancer cells. Breast cancer (SKBR3) and ovarian cancer (SKOV3) cell lines are our models for biological assessment. The data revealed that nimesulide analogs showed high cytotoxicity when treated with SKBR3 cell line ranges from 0.22 µM to 12.0 µM, while SKOV3 cell line from 0.1 µM to 16.0 µM. In-depth, structure-activity relationship applied on nimesulide lead structure highlights the importance of a bulk moiety on position two that reduces cell proliferation in both cell lines.

[1]  F. Alanazi,et al.  Development of nimesulide analogs as a dual inhibitor targeting tubulin and HSP27 for treatment of female cancers , 2022, Journal of Molecular Structure.

[2]  L. A. Alhadad.  Encapsulation and In Vitro Evaluation of Low-Density Lipoprotein with Cholesterol Conjugated Anti-HSP27 and HER2 Proteins as Drug Delivery Enhancement in Ovarian Cancer , 2021, Biomedical Journal of Scientific & Technical Research.

[3]  Amal Al‐Azmi,et al.  Efficient synthesis of Triazolo[4,5-d]pyrimidine-7-carbonitriles and Imidazole-4,5-dicarbonitriles using Triethylorthoalkylates and their structural characterisation by Single-crystal x-ray diffraction , 2021, Kuwait Journal of Science.

[4]  F. Alanazi,et al.  Design and encapsulation of anticancer dual HSP27 and HER2 inhibitor into low density lipoprotein to target ovarian cancer cells , 2020, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[5]  B. Vellingiri,et al.  Therapeutic potential of Hsp27 in neurological diseases , 2019, Egyptian Journal of Medical Human Genetics.

[6]  Laila A. Jaragh-Alhadad.  In-vitro evaluation of HSP27 inhibitors function through HER2 pathway for ovarian cancer therapy , 2018, Translational Cancer Research.

[7]  M. R. Aberturas,et al.  Nimesulide-loaded nanoparticles for the potential coadjuvant treatment of prostate cancer. , 2015, International journal of pharmaceutics.

[8]  G. Alexiou,et al.  The role of heat shock proteins in cancer. , 2015, Cancer letters.

[9]  E. Kaigorodova,et al.  Heat shock proteins as prognostic markers of cancer. , 2014, Current cancer drug targets.

[10]  M. Gleave,et al.  Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. , 2014, European urology.

[11]  Maria Kavallaris,et al.  Microtubules and Their Role in Cellular Stress in Cancer , 2014, Front. Oncol..

[12]  R. Bergan,et al.  Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression , 2014, Oncotarget.

[13]  D. Musiani,et al.  HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor , 2014, International journal of cancer.

[14]  C. Garrido,et al.  Targeting heat shock proteins in cancer. , 2013, Cancer letters.

[15]  D. Petrylak,et al.  Tubulin-targeted agents including docetaxel and cabazitaxel. , 2013, Cancer journal.

[16]  D. Musiani,et al.  HSP 27 is required for invasion and metastasis triggered by hepatocyte growth factor , 2013 .

[17]  E. Ratner,et al.  Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel , 2013, Clinical & Experimental Metastasis.

[18]  M. Gleave,et al.  Small heat shock proteins in cancer therapy and prognosis. , 2012, The international journal of biochemistry & cell biology.

[19]  N. Wilson,et al.  Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target , 2012, Fibrogenesis & tissue repair.

[20]  Yongxiang Yin,et al.  Increased expression of heat shock protein 27 correlates with peritoneal metastasis in epithelial ovarian cancer. , 2012, Reproductive sciences.

[21]  L. Kim,et al.  Heat Shock Protein as Molecular Targets for Breast Cancer Therapeutics , 2011, Journal of breast cancer.

[22]  S. Simon,et al.  Dynamic processes that reflect anti-apoptotic strategies set up by HspB1 (Hsp27). , 2010, Experimental cell research.

[23]  Chryso Kanthou,et al.  Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies , 2009, International journal of experimental pathology.

[24]  Zhiwei Wang,et al.  Copper conjugates of nimesulide Schiff bases targeting VEGF, COX and Bcl-2 in pancreatic cancer cells. , 2007, Journal of inorganic biochemistry.

[25]  S. C. Lakhotia,et al.  Heat shock genes — integrating cell survival and death , 2007, Journal of Biosciences.

[26]  Jeffrey R. Jackson,et al.  Targeted anti-mitotic therapies: can we improve on tubulin agents? , 2007, Nature Reviews Cancer.

[27]  G. Kroemer,et al.  Heat Shock Proteins 27 and 70: Anti-Apoptotic Proteins with Tumorigenic Properties , 2006, Cell cycle.

[28]  G. Ferns,et al.  Heat shock protein 27: its potential role in vascular disease , 2006, International journal of experimental pathology.

[29]  H. Mao,et al.  High-pressure vibrational spectroscopy of sulfur dioxide. , 2005, The Journal of chemical physics.

[30]  K. Lyseng-Williamson,et al.  Docetaxel: a review of its use in metastatic breast cancer. , 2005, Drugs.

[31]  J. Smyth,et al.  Expression of the heat shock protein HSP27 in human ovarian cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.